Possible increased risk of Epstein-Barr virus (EBV) infection and post-transplant lymphoproliferative disease (PTLD) in letermovir-exposed haematopoietic cell transplantation recipients.

Prevymis (letermovir) - Merck (MSD)

Possible increased risk of Epstein-Barr virus (EBV) infection and post-transplant lymphoproliferative disease (PTLD) in letermovir-exposed haematopoietic cell transplantation recipients. (PubMed, J Antimicrob Chemother) - Sep 23, 2025 - No abstract available
Journal • Epstein-Barr Virus Infections • Infectious Disease • Transplantation

http://www.ncbi.nlm.nih.gov/pubmed/40985145

Anthony D Anderson; Jose F Camargo; Saanvi S Singireddy

Sep 23, 2025